Objective: To evaluate the efficacy of transcranial magnetic stimulation with patients with Parkinson diseases.

Background: Parkinson’s disease is one of the most common causes of disability among older adults. Several cognitive functions are affected in the early phase by the progress of the degeneration and this could increase the risk of developing dementia. Patients with Parkinson’s may develop depression and emotional processing impairments. Therefore, different modalities have evolved to manage these symptoms in addition to medical treatment.

Method: For this narrative review, we conducted an electronic search through Pubmed, Cochrane Central Register of Clinical Trials, Web of Science (WOS), and Scopus databases. The search was narrowed to randomized controlled articles. A total of 400 materials were initially identified to be potentially relevant for the review. A total of five articles were included, and they were found to match the inclusion criteria.

Results: A total of five randomized clinical trials met our inclusion criteria and were included in this narrative review. Regarding cognition, one paper concluded that cognition has increased significantly in the interventional group with improvements in the attention and visuospatial domains of the brain. While the other study showed that the interventional group showed significant improvement in RBANS and MOCA scores which was correlated with improvement in Radiotracer uptake in the bilateral basal ganglion. Concerning Speech, after the application of the intervention on 33 PD patients, it was reported that the active group showed an increase in the activation of the orofacial sensorimotor cortex and caudate nucleus and the connectivity of the stimulated regions. A study reported that the application of TMS not only improve the depression status of the patients but also boosted their health-related quality of life and motor skills. On the other hand, another study concluded that the efficacy of escitalopram and pramipexole was superior to rTMS on the HAMD score.

Conclusion: Transcranial magnetic stimulation is considered as an effective intervention and can be used to improve cognitive functions, speech disorders and depression in patients with Parkinson disease. However, there is no enough evidence supporting its use in clinical practice due to the low number of high quality randomized clinical trials.

References: No

« Back to 2023 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/narrative-review-of-the-efficacy-of-the-efficacy-of-transcranial-magnetic-stimulation-with-patients-with-parkinson-disease/